POTENTIAL NEW CANCER THERAPIES ON THE HORIZON

Investigational product candidates in the Dendreon pipeline include:

  • ACI Product Candidates:
    • DN24-02, an ACI targeted at the HER 2/neu receptor
    • Dendreon has in-licensed 2 additional antigen targets, carbonic anhydrase IX (CA9) and carcinoembryonic antigen (CEA), for the development of ACI candidates. Product candidates targeted at CA9 are in preclinical development for the treatment of kidney, colon, and cervical cancer. Product candidates targeted at CEA are in preclinical development for the treatment of breast, lung, and colon cancer